MUMBAI, India, July 5 -- Intellectual Property India has published a patent application (202517056266 A) filed by Takeda Vaccines, Inc., Cambridge, U.S.A., on June 11, for 'a method for the quantitative determination of human serum albumin monomer in virus-containing pharmaceutical compositions.'
Inventor(s) include Somanadhan, Brinda.
The application for the patent was published on July 4, under issue no. 27/2025.
According to the abstract released by the Intellectual Property India: "The present invention relates to methods for the quantitative determination of human serum albumin (HSA) monomer in virus-containing, in particular flavivirus, pharmaceutical compositions. The present invention also relates to the use of the methods in the quality control of virus-containing pharmaceutical compositions. In a further aspect the present invention also relate to the use of the inventive methods for monitoring the long-term stability of the HSA monomer in virus-containing pharmaceutical formulations."
The patent application was internationally filed on Nov. 28, 2023, under International application No.PCT/US2023/081243.
Disclaimer: Curated by HT Syndication.
